LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has commenced an underwritten offering of $300 million of its ordinary shares. LivaNova also intends to grant the underwriters of the offering a 30-day option to acquire up to an additional 15% of the ordinary shares […]
Other News
Investor Insights: Paul LaViolette, Managing Partner and COO of SV Health
Investor Insights highlights some of the top investors in Life Science and MedTech. This week, host Ken Dropiewski interviews Paul LaViolette: managing partner and COO of SV Health Investors. They discuss a range of topics: from the timing of investments to the focus on big ideas within the industry.
ABBOTT INTRODUCES JOT DX™ INSERTABLE CARDIAC MONITOR, DESIGNED TO REDUCE DATA BURDEN AND IMPROVE ACCURATE DIAGNOSIS OF DIFFICULT-TO-DETECT ABNORMAL HEART RHYTHMS
– Jot Dx™ Insertable Cardiac Monitor (ICM) expands Abbott’s connected care portfolio and is the first and only device on the market with the option to control the amount of electronic data received for irregular heart rhythms, depending on the unique needs of the patient or clinic – Jot Dx™ […]
Orchestra BioMed™ Announces Clinical Data Demonstrating a Significant and Sustained Reduction in Blood Pressure in MODERATO II Control Patients After Crossover to BackBeat Cardiac Neuromodulation Therapy™
Clinically meaningful and statistically significant reduction in systolic blood pressure is consistent with the decrease previously observed in the study treatment group during the same time period. Ambulatory Systolic Blood Pressure (aSBP) decreased by an average of 10.3 mmHg (p<0.01) at 6 months. Office Systolic Blood Pressure (oSBP) decreased by an average […]
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif., July 29, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2021. Second Quarter Highlights and 2021 Outlook Sales rebounded and grew 49 percent to $1.4 billion; underlying1 sales grew 44 percent TAVR sales exceeded expectations and grew 52 percent; underlying sales grew 48 percent EPS […]
Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer
THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021. Dr. Granowitz joins Lexicon with deep and successful leadership experience in the pharmaceutical industry, having […]
Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today the pricing of its underwritten, upsized initial public offering of 12,000,000 shares of its common stock at an […]
Cardinal Health completes sale of Cordis business to Hellman & Friedman
DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health’s Cordis business to H&F. The sale price of approximately $1 billion includes the buyer’s assumption of certain liabilities and the seller’s retention of certain working capital accounts. […]
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
– Ionis-discovered pelacarsen continues to advance as potential first new therapy for Lp(a)-driven cardiovascular disease CARLSBAD, Calif., Aug. 2, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for exclusive worldwide development and commercialization, continues to advance in the clinic as the potential […]
UPTRAVI® (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)
New formulation allows for uninterrupted treatment for PAH patients temporarily unable to take oral therapy TITUSVILLE, N.J., July 30, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved UPTRAVI® (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial […]
Recent
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve
Rad AI Appoints Chief Operating Officer and First Chief Clinical Officer, Strengthening Operational and Clinical Strategy
Popular
- No commented posts yet